SEARCH

SEARCH BY CITATION

References

  • 1
    Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005; 129: 565576.
  • 2
    Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella R. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006; 8(6): 18.
  • 3
    Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004; 25: 961966.
  • 4
    Ali IU, Luke BT, Dean M, Greenwald P. Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer. 2005; 93: 953959.
  • 5
    Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V, Bellvitge Colorectal Cancer Study Group. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/ COX2) and risk of colorectal cancer. Br J Cancer. 2004; 91: 339343.
  • 6
    Koh WP, Yuan JM, va den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer. 2004; 90: 1,7601,764.
  • 7
    Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D, et al. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a chinese population. Gastroenterology. 2006; 130: 1,9751,984.
  • 8
    Kang S, Kim YB, Kim MH, Yoon KS, Kim JW, Park NH, Song YS, Kang D, Yoo KY, Kang SB, et al. Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett. 2005; 217: 1116.
  • 9
    Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004; 25: 229235.
  • 10
    Hu Z, Miao X, Ma H, Wang X, Tan W, Wei Q, Lin D, Shen H. A common polymorphism in the 3′UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer. 2005; 48: 1117.
  • 11
    Park JM, Choi JE, Chae MH, Lee WK, Cha SI, Son JW, Kim CH, Kam S, Kang YM, Jung TH, et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer. 2006; 6: 70: 17.
  • 12
    Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998; 12: 1,0631,073.
  • 13
    Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004; 56: 387437.
  • 14
    Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis. 2005; 26: 449457.
  • 15
    Ashktorab H, Tsang S, Luke B, Sun Z, Adam-Campbell L, Kwagyan J, Poirier R, Akter S, Akhgari A, Smoot D, et al. Protective effect of Cox-2 allelic variants on risk of colorectal adenoma development in African Americans. Anticancer Res. 2008; 28(5B): 3,1193,123.
  • 16
    Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J. PTGS2 (COX-2) −765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev. 2005; 14: 616619.
  • 17
    Campa D, Hung RJ, Mates D, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Bencko V, Foretova L, et al. Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14: 538539.
  • 18
    Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, et al. The structure of haplotype blocks in the human genome. Science. 2002; 296: 2,2252,229.
  • 19
    Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High resolution haplotype structure in the human genome. Nat Genet. 2001; 29: 229232.
  • 20
    Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68: 978989.
  • 21
    Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003; 73: 1,1621,169.
  • 22
    Fedorova L, Fedorov A. Introns in gene evolution. Genetica. 2003; 118: 123131.
  • 23
    Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003; 4: 431436.
  • 24
    Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2: 544551.
  • 25
    Dannenberg AJ, Howe LR. The role of COX-2 in breast and cervical cancer. Prog Exp Tumor Res. 2003; 37: 90106.
  • 26
    Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125140.